Wolfe Research Now Offering Coverage of Guardant Health

🌥️Trending News

Wolfe Research is thrilled to announce that they are now providing coverage of Guardant Health ($NASDAQ:GH). Guardant Health, Inc. is a precision oncology company focused on helping conquer cancer. Through its non-invasive liquid biopsy product and services, Guardant Health has become the global leader in advanced, non-invasive cancer diagnostics. Their products provide oncologists with rapid data about a patient’s cancer, allowing them to make the most informed decisions about how to best treat their cancer. Guardant Health’s mission is to leverage their product to improve outcomes and reduce healthcare costs.

In addition, they are actively investing in research and development to bring more innovative cancer treatments to market. With Wolfe Research now providing coverage of Guardant Health, investors can stay up to date on the latest developments in the oncology space.

Stock Price

GUARDANT HEALTH stock opened at $28.1 on Monday and closed at $27.2, down by 3.4% from its prior closing price of 28.2. This decrease in stock price is likely due to uncertainty about the company’s plans for the future and investor skepticism about its potential. With the addition of Wolfe Research coverage, investors now have access to higher quality data and analysis about GUARDANT HEALTH which may help them make better informed decisions about their investments in the company. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Guardant Health. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Guardant Health. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Guardant Health. More…

Key Ratios Snapshot

Some of the financial key ratios for Guardant Health are shown below. More…

Analysis

GoodWhale has conducted an analysis of GUARDANT HEALTH‘s financials and based on our Star Chart, GUARDANT HEALTH has a low health score of 3/10 with regard to its cashflows and debt. This indicates that it is less likely to sustain future operations in times of crisis. Furthermore, GUARDANT HEALTH is strong in growth, medium in asset and weak in dividend, profitability. Based on this information we have classified GUARDANT HEALTH as a ‘cheetah’ type of company. This is a company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are comfortable with the risks associated with this kind of company may be interested in investing in GUARDANT HEALTH. These investors may be attracted to the company’s potential for growth, despite the risks, as well as the potential for higher returns if the company does perform well. However, investors should consider the risks associated with investing in such a company and understand that there is a possibility that the returns may not meet expectations. More…

Peers

The competition in the market for cancer detection and treatment is heating up. Guardant Health Inc, a leading player in the field, is up against some stiff competition from the likes of Aclaris Therapeutics Inc, Inoviq Ltd, and Biomark Diagnostics Inc. All these companies are vying for a share of the pie in this rapidly growing market. While Guardant Health Inc has a strong product portfolio and a good track record, its competitors are not far behind and are also making inroads into this market. It remains to be seen who will emerge victorious in this battle.

– Aclaris Therapeutics Inc ($NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of dermatological and immuno-inflammatory diseases. The company’s lead product candidates include ATI-502 for the treatment of seborrheic keratosis, and ATI-501 for the treatment of vitiligo. Aclaris Therapeutics Inc has a market cap of 1.11B as of 2022, a Return on Equity of -25.42%.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd is a publicly traded company with a market capitalization of 50.61M as of 2022. The company’s return on equity (ROE) is -13.68%. Inoviq Ltd is engaged in the development and commercialization of innovative drugs and therapies. The company’s products are designed to improve the lives of patients with serious medical conditions. Inoviq’s products are available in more than 60 countries worldwide.

– Biomark Diagnostics Inc ($OTCPK:BMKDF)

Biomark Diagnostics Inc is a company that provides diagnostic testing services. The company has a market capitalization of 10.88 million as of 2022 and a return on equity of 179.57%. The company’s diagnostic testing services include tests for cancer, cardiovascular disease, and infectious diseases. Biomark Diagnostics Inc is headquartered in the United States.

Summary

Investing in Guardant Health can be a worthwhile endeavor, as the company has seen strong growth in its stock price.

However, Wolfe Research’s recent coverage of Guardant Health has caused the stock price to dip. Despite this, analysts have noted that Guardant Health is well-positioned to benefit from its unique products and services, which focus on precision cancer diagnostics and monitoring.

In addition, the company has made significant investments in research and development, which has been instrumental in its continued success. Therefore, investors should continue to monitor the performance of Guardant Health and consider initiating a position in the firm if opportunities arise.